NewAmsterdam Pharma Company NAMS Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's total operating expenses?
- NewAmsterdam Pharma Company (NAMS) reported total operating expenses of $61.46M in Q1 2026.
- How has NewAmsterdam Pharma Company's total operating expenses changed year-over-year?
- NewAmsterdam Pharma Company's total operating expenses decreased by 14.5% year-over-year, from $71.9M to $61.46M.
- What is the long-term trend for NewAmsterdam Pharma Company's total operating expenses?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's total operating expenses has grown at a 63.2% compound annual growth rate (CAGR), from $34.98M to $248.19M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.